Peter A. Riedell

5.8k total citations · 2 hit papers
114 papers, 1.5k citations indexed

About

Peter A. Riedell is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Peter A. Riedell has authored 114 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Oncology, 34 papers in Pathology and Forensic Medicine and 29 papers in Immunology. Recurrent topics in Peter A. Riedell's work include CAR-T cell therapy research (80 papers), Lymphoma Diagnosis and Treatment (34 papers) and Chronic Lymphocytic Leukemia Research (23 papers). Peter A. Riedell is often cited by papers focused on CAR-T cell therapy research (80 papers), Lymphoma Diagnosis and Treatment (34 papers) and Chronic Lymphocytic Leukemia Research (23 papers). Peter A. Riedell collaborates with scholars based in United States, Canada and France. Peter A. Riedell's co-authors include Sonali M. Smith, Olalekan O. Oluwole, Michael R. Bishop, Joseph P. McGuirk, Kenneth R. Carson, Veronika Bachanová, Miguel‐Angel Perales, Loretta J. Nastoupil, David L. Porter and Richard T. Maziarz and has published in prestigious journals such as The Lancet, Nature Medicine and Nature Communications.

In The Last Decade

Peter A. Riedell

103 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial

2022 186 citations Sattva S. Neelapu, Michael Dickinson et al. Nature Medicine profile →
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial

2025 42 citations Armin Ghobadi, Veronika Bachanová et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter A. Riedell United States	20	1.1k	532	264	235	221	114	1.5k
Chaitra S. Ujjani United States	15	622 0.6×	487 0.9×	97 0.4×	234 1.0×	156 0.7×	92	855
Taiga Nishihori United States	22	751 0.7×	235 0.4×	390 1.5×	231 1.0×	344 1.6×	169	1.7k
Jacob D. Soumerai United States	20	780 0.7×	1000 1.9×	209 0.8×	1.1k 4.8×	475 2.1×	93	1.9k
Martina Chiarucci Italy	6	904 0.9×	1.3k 2.4×	108 0.4×	323 1.4×	190 0.9×	10	1.7k
Melhem Solh United States	26	1.2k 1.1×	529 1.0×	238 0.9×	308 1.3×	586 2.7×	136	2.1k
Giuseppe Gritti Italy	17	651 0.6×	628 1.2×	131 0.5×	298 1.3×	392 1.8×	59	1.2k
Anne Beaven United States	19	511 0.5×	556 1.0×	186 0.7×	170 0.7×	209 0.9×	89	956
B. Glaß Germany	21	611 0.6×	624 1.2×	100 0.4×	280 1.2×	403 1.8×	55	1.2k
Renata Zaucha Poland	16	455 0.4×	133 0.3×	130 0.5×	166 0.7×	147 0.7×	54	1.1k
Ronit Gurion Israel	17	381 0.4×	344 0.6×	100 0.4×	216 0.9×	102 0.5×	83	830

Countries citing papers authored by Peter A. Riedell

Since Specialization

Citations

This map shows the geographic impact of Peter A. Riedell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter A. Riedell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter A. Riedell more than expected).

Fields of papers citing papers by Peter A. Riedell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter A. Riedell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter A. Riedell. The network helps show where Peter A. Riedell may publish in the future.

Co-authorship network of co-authors of Peter A. Riedell

This figure shows the co-authorship network connecting the top 25 collaborators of Peter A. Riedell. A scholar is included among the top collaborators of Peter A. Riedell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter A. Riedell. Peter A. Riedell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sawalha, Yazeed, Shayna Sarosiek, Sudip Thapa, et al.. (2025). Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis. Blood Cancer Journal. 15(1). 65–65. 1 indexed citations

Chávez, Julio C., Michael Dickinson, Javier Muñoz, et al.. (2025). Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study. Blood. 145(20). 2303–2311. 3 indexed citations

Landsburg, Daniel J., Matthew J. Frigault, S.R. Foley, et al.. (2025). Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry. Journal for ImmunoTherapy of Cancer. 13(2). e009890–e009890. 3 indexed citations

Miklos, David B., et al.. (2025). Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review. Targeted Oncology. 20(2). 217–234. 2 indexed citations

Cao, Guoshuai, Erting Tang, Jun Wan, et al.. (2025). Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma. Nature Communications. 16(1). 4205–4205. 2 indexed citations

Ghobadi, Armin, Veronika Bachanová, Krish Patel, et al.. (2025). Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. The Lancet. 405(10473). 127–136. 42 indexed citations breakdown →

Roloff, Gregory W., Satyajit Kosuri, Adam DuVall, et al.. (2024). Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 109(11). 3739–3744. 1 indexed citations

Rojek, Alexandra E., Nausheen Ahmed, Sairah Ahmed, et al.. (2024). CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium. Blood. 144(Supplement 1). 4503–4503.

Ahmed, Gulrayz, Anikó Szabó, Mazyar Shadman, et al.. (2024). CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience. Blood Advances. 8(13). 3528–3531. 2 indexed citations

10.

Fowler, Nathan, Julio C. Chávez, & Peter A. Riedell. (2024). Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review. Targeted Oncology. 19(4). 495–510. 3 indexed citations

11.

Gong, He, Theodore Karrison, Wendy Stock, et al.. (2024). FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients. Annals of Translational Medicine. 12(3). 49–49.

12.

Williamson, Staci, Jamie Brower, Veronika Bachanová, et al.. (2023). Prolonged Cytopenias after Commercial CAR T-Cell Therapy with Tisagenlecleucel and Axicabtagene Ciloleucel for Relapsed and Refractory DLBCL. Transplantation and Cellular Therapy. 29(2). S220–S221. 1 indexed citations

13.

Gong, He, Theodore Karrison, Wendy Stock, et al.. (2023). Eltrombopag Is a Safe and Effective Agent to Treat Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). Transplantation and Cellular Therapy. 29(2). S142–S143.

14.

Neelapu, Sattva S., Michael Dickinson, Javier Muñoz, et al.. (2022). Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nature Medicine. 28(4). 735–742. 186 indexed citations breakdown →

15.

Rojek, Alexandra E., Justin Kline, Daniel Appelbaum, et al.. (2021). Impact of Pre-Treatment Whole-Body Metabolic Tumor Volume on Toxicities and Outcomes in Patients Treated with Anti-CD19 CAR T-Cell Therapy for Aggressive Large B-Cell NHL. Transplantation and Cellular Therapy. 27(3). S193–S194. 1 indexed citations

16.

Yu, Jovian, Brian C.‐H. Chiu, Timothy Carll, et al.. (2021). Loss of 5-hydroxymethylcytosine expression is near-universal in B-cell lymphomas with variable mutations in epigenetic regulators. Haematologica. 107(4). 966–969. 3 indexed citations

17.

Jacobson, Caron A., Frederick L. Locke, David B. Miklos, et al.. (2020). Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product. Blood. 136(Supplement 1). 2–3. 7 indexed citations

18.

Kothari, Shawn, Andrew Artz, Sang Mee Lee, et al.. (2020). Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. Bone Marrow Transplantation. 55(6). 1161–1168. 11 indexed citations

19.

Jaeger, Ulrich, Nina Worel, Joseph P. McGuirk, et al.. (2019). Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood. 134(Supplement_1). 5325–5325. 17 indexed citations

20.

Carson, Kenneth R., Peter A. Riedell, Ryan C. Lynch, et al.. (2015). Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. Journal of Geriatric Oncology. 6(3). 211–218. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact